Rabusertib (BioDeep_00000015476)
代谢物信息卡片
化学式: C18H22BrN5O3 (435.09059220000006)
中文名称: LY2603618
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC(=C(C=C1Br)NC(=O)NC2=NC=C(N=C2)C)OCC3CNCCO3
InChI: InChI=1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:124917
- KEGG: C77108
- KEGGdrug: D10397
- PubChem: 11955855
- DrugBank: DB11662
- ChEMBL: CHEMBL3039517
- CAS: 911222-45-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Lydia E Hainley, Martina S Hughson, Amithi Narendran, Ralph Smith, Justin Arthur, Alida Hayner-Buchan, David J Conti, John M Lehman, Thomas D Friedrich. Chk1 and the Host Cell DNA Damage Response as a Potential Antiviral Target in BK Polyomavirus Infection.
Viruses.
2021 07; 13(7):. doi:
10.3390/v13071353. [PMID: 34372559] - Emiliano Calvo, Fadi Braiteh, Daniel Von Hoff, Robert McWilliams, Carlos Becerra, Matthew D Galsky, Gayle Jameson, Ji Lin, Scott McKane, Enaksha R Wickremsinhe, Scott M Hynes, Aimee Bence Lin, Karla Hurt, Donald Richards. Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Oncology.
2016; 91(5):251-260. doi:
10.1159/000448621. [PMID: 27598338] - Toshihiko Doi, Takayuki Yoshino, Kohei Shitara, Nobuaki Matsubara, Nozomu Fuse, Yoichi Naito, Kazunori Uenaka, Takashi Nakamura, Scott M Hynes, Aimee Bence Lin. Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.
Anti-cancer drugs.
2015 Nov; 26(10):1043-53. doi:
10.1097/cad.0000000000000278. [PMID: 26288133] - Scott M Hynes, Enaksha Wickremsinhe, Wei Zhang, Rodney Decker, Jennifer Ott, Jason Chandler, Malcolm Mitchell. Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
Biopharmaceutics & drug disposition.
2015 Jan; 36(1):49-63. doi:
10.1002/bdd.1922. [PMID: 25296725] - Enaksha R Wickremsinhe, Scott M Hynes, Margo D Palmieri, Malcolm I Mitchell, Trent L Abraham, Jessica Fayer Rehmel, Emilie Chana, Lorenz M Jost, Kenneth C Cassidy. Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors.
Xenobiotica; the fate of foreign compounds in biological systems.
2014 Sep; 44(9):827-41. doi:
10.3109/00498254.2014.900589. [PMID: 24666335]